Active Biotech Q4 2024: Funded through 2025 - Redeye

Redeye comments on Active Biotech’s Q4 report. The main event in the quarter was the oversubscribed rights issue. Laquinimod’s biodistribution study is the next main trigger while tasquinimod is slowly approaching the recruitment of the first patients in myelofibrosis.

Länk till analysen i sin helhet: https://www.redeye.se/research/1077380/active-biotech-q4-2024-funded-through-2025?utm_source=finwire&utm_medium=RSS